Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 24, 2024 - Issue 4
Submit an article Journal homepage
496
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Revolutionizing the management of patients with atopic dermatitis: practical considerations

Filomena RussoDepartment of Dermatology, IDI-IRCCS, Dermatological Research Hospital, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2780-7720View further author information
ORCID Icon,
Anna Rita GiampetruzziDepartment of Dermatology, IDI-IRCCS, Dermatological Research Hospital, Rome, ItalyView further author information
,
Maria Antonietta PillaDepartment of Dermatology, IDI-IRCCS, Dermatological Research Hospital, Rome, ItalyView further author information
,
Ornella De PitàDepartment of Dermatology, IDI-IRCCS, Dermatological Research Hospital, Rome, ItalyView further author information
&
Elisa CamelaDepartment of Dermatology, IDI-IRCCS, Dermatological Research Hospital, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-7201-9163View further author information
ORCID Icon
Pages 213-215 | Received 20 Jan 2024, Accepted 20 Mar 2024, Published online: 24 Mar 2024

References

  • Arkwright PD, Koplin JJ. Impact of a decade of research into atopic dermatitis. J Allergy Clin Immunol Pract. 2023 Jan;11(1):63–71. doi: 10.1016/j.jaip.2022.09.021
  • Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. doi: 10.1016/S0140-6736(17)31191-1
  • Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019 Sep;181(3):459–473.
  • Russo F, Rizzo A, Santi F, et al. A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis. Int J Dermatol. 2022 Jun;61(6):e204–e206.
  • Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like Eruption triggered by Dupilumab Therapy. Dermatitis. 2021 Nov 01;32(6):e147–e148. doi: 10.1097/DER.0000000000000740
  • Wollenberg A, Beck LA, de Bruin Weller M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–65. doi: 10.1111/bjd.20810
  • Kim RW, Lam M, Abuabara K, et al. Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol. 2024 Jan 12;25(2):179–193. doi: 10.1007/s40257-023-00837-w
  • Tokareva K, Reid P, Yang V, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul;19(11):1385–1397.
  • Perche PO, Cook MK, Feldman SR Abrocitinib: a new FDA-Approved drug for moderate-to-severe atopic dermatitis. Ann Pharmacother. 2023 Jan;57(1):86–98. doi: 10.1177/10600280221096713
  • Hoy SM Baricitinib: a review in moderate to severe atopic dermatitis. Am J Clin Dermatol. 2022 May;23(3):409–420. doi: 10.1007/s40257-022-00684-1
  • Chovatiya R, Paller AS JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021 Oct;148(4):927–940. doi: 10.1016/j.jaci.2021.08.009
  • Teng Y, Zhong H, Yang X, et al. Current and emerging therapies for atopic dermatitis in the elderly. Clin Interv Aging. 2023 Oct 2;18:1641–1652. doi: 10.2147/CIA.S426044
  • Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523–32. doi: 10.1001/jamadermatol.2022.0455
  • Facheris P, Jeffery J, Del Duca E, et al. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023 May;20(5):448–474.
  • Chiricozzi A, Maurelli M, Calabrese L, et al. Overview of atopic dermatitis in different ethnic groups. J Clin Med. 2023 Apr 4;12(7):2701. doi: 10.3390/jcm12072701

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.